2022 AMI Online Salon

XL092: An investigational multi-receptor tyrosine kinase inhibitor

Project Detail

  • Entrant Name:  Sonya Amin
  • Client: Exelixis
  • Copyright: Exelixis, Inc, 2022
  • Medium/software used: HTML, CSS, JS
  • Final presentation format: HTML web application
  • Primary Audience: Healthcare providers (HCPs)

Project Description

With an expanding oncology pipeline, our client was seeking an educational asset to drive awareness and interest in a new investigational compound, the multi-receptor tyrosine kinase (RTK) inhibitor XL092. Emphasizing the rigorous scientific evidence backing the XL092 clinical program was of prime importance for our client. To keep busy HCPs engaged while still comprehensively covering the science underlying the XL092 mechanism of action, we consolidated the content into shorter, easy-to-digest clips, each focusing on one key message. The clips were housed in an intuitive, easy-to-use web app that allowed HCPs to explore at their own pace. Designed for self-guided exploration, users can jump to clips of interest using the playlist menu and scrub through footage using the playback controls. The application is responsive and can be used on any device, including desktop, mobile devices, and touch screens, both on the web and in offline congress settings.